Clinical Significance of MicroRNAs in Chronic and Acute Human Leukemia

Overview

Journal Mol Cancer

Publisher Biomed Central

Specialties Molecular Biology
Oncology

Date 2016 May 16

PMID 27179712

Citations 73

Authors

Chien-Hung Yeh

Ramona Moles

Christophe Nicot

Affiliations

Soon will be listed here.

Abstract

Small non-coding microRNAs (miRNAs) are epigenetic regulators that target specific cellular mRNA to modulate gene expression patterns and cellular signaling pathways. miRNAs are involved in a wide range of biological processes and are frequently deregulated in human cancers. Numerous miRNAs promote tumorigenesis and cancer progression by enhancing tumor growth, angiogenesis, invasion and immune evasion, while others have tumor suppressive effects (Hayes, et al., Trends Mol Med 20(8): 460-9, 2014; Stahlhut and Slack, Genome Med 5 (12): 111, 2013). The expression profile of cancer miRNAs can be used to predict patient prognosis and clinical response to treatment (Bouchie, Nat Biotechnol 31(7): 577, 2013). The majority of miRNAs are intracellular localized, however circulating miRNAs have been detected in various body fluids and represent new biomarkers of solid and hematologic cancers (Fabris and Calin, Mol Oncol 10(3):503-8, 2016; Allegra, et al., Int J Oncol 41(6): 1897-912, 2012). This review describes the clinical relevance of miRNAs, lncRNAs and snoRNAs in the diagnosis, prognosis and treatment response in patients with chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML) and acute adult T-cell leukemia (ATL).

Citing Articles

Chromato-kinetic fingerprinting enables multiomic digital counting of single disease biomarker molecules.

Banerjee P, Ray S, Dai L, Sandford E, Chatterjee T, Mandal S bioRxiv. 2025; .

PMID: 39975368 PMC: 11838488. DOI: 10.1101/2025.01.31.636009.

Dual roles of extracellular vesicles in acute lymphoblastic leukemia: implications for disease progression and theranostic strategies.

Lajevardi M, Ashrafpour M, Mubarak S, Rafieyan B, Kiani A, Noori E Med Oncol. 2024; 42(1):11.

PMID: 39572459 PMC: 11582151. DOI: 10.1007/s12032-024-02547-7.

Translating molecular insights into clinical success: alkaloid-based therapies for leukemia.

Goleij P, Tabari M, Rezaee A, Sanaye P, Daglia M, Alijanzadeh D Naunyn Schmiedebergs Arch Pharmacol. 2024; .

PMID: 39476244 DOI: 10.1007/s00210-024-03540-7.

DNA Damage-Inducing 10-Methoxy-canthin-6-one (Mtx-C) Promotes Cell Cycle Arrest in G/M and Myeloid Differentiation of Acute Myeloid Leukemias and Leukemic Stem Cells.

Torquato H, Rodrigues Junior M, Lima C, de Araujo Junior R, Soares C, Domiciano A ACS Omega. 2024; 9(35):37343-37354.

PMID: 39246489 PMC: 11375717. DOI: 10.1021/acsomega.4c05435.

The impact of COVID-19 on microRNA and CD marker expression in AML patients.

Saeed R, Abdulrahman Z, Mohammad D Sci Rep. 2024; 14(1):14251.

PMID: 38902412 PMC: 11190249. DOI: 10.1038/s41598-024-64775-1.

References

Garzon R, Garofalo M, Martelli M, Briesewitz R, Wang L, Fernandez-Cymering C . Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci U S A. 2008; 105(10):3945-50. PMC: 2268779. DOI: 10.1073/pnas.0800135105. View

Valeri N, Gasparini P, Fabbri M, Braconi C, Veronese A, Lovat F . Modulation of mismatch repair and genomic stability by miR-155. Proc Natl Acad Sci U S A. 2010; 107(15):6982-7. PMC: 2872463. DOI: 10.1073/pnas.1002472107. View

Zoni E, Kruithof-de Julio M, van der Pluijm G . miR-25, integrin and cancer invasiveness. Oncoscience. 2015; 2(8):663-4. PMC: 4580050. DOI: 10.18632/oncoscience.214. View

Chuang M, Chiu Y, Chou W, Hou H, Chuang E, Tien H . A 3-microRNA scoring system for prognostication in de novo acute myeloid leukemia patients. Leukemia. 2014; 29(5):1051-9. DOI: 10.1038/leu.2014.333. View

Yeh Y, Ozer H, Lehman A, Maddocks K, Yu L, Johnson A . Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling. Blood. 2015; 125(21):3297-305. PMC: 4440883. DOI: 10.1182/blood-2014-12-618470. View

Garzon R, Volinia S, Liu C, Fernandez-Cymering C, Palumbo T, Pichiorri F . MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood. 2008; 111(6):3183-9. PMC: 2265455. DOI: 10.1182/blood-2007-07-098749. View

Allegra A, Alonci A, Campo S, Penna G, Petrungaro A, Gerace D . Circulating microRNAs: new biomarkers in diagnosis, prognosis and treatment of cancer (review). Int J Oncol. 2012; 41(6):1897-912. DOI: 10.3892/ijo.2012.1647. View

Zhou K, Yi S, Yu Z, Li Z, Wang Y, Zou D . MicroRNA-223 expression is uniformly down-regulated in B cell lymphoproliferative disorders and is associated with poor survival in patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2011; 53(6):1155-61. DOI: 10.3109/10428194.2011.642303. View

Nemes K, Csoka M, Nagy N, Mark A, Varadi Z, Danko T . Expression of certain leukemia/lymphoma related microRNAs and its correlation with prognosis in childhood acute lymphoblastic leukemia. Pathol Oncol Res. 2014; 21(3):597-604. DOI: 10.1007/s12253-014-9861-z. View

10.

Guo G, Kang Q, Zhu X, Chen Q, Wang X, Chen Y . A long noncoding RNA critically regulates Bcr-Abl-mediated cellular transformation by acting as a competitive endogenous RNA. Oncogene. 2014; 34(14):1768-79. DOI: 10.1038/onc.2014.131. View

11.

Swellam M, El-Khazragy N . Clinical impact of circulating microRNAs as blood-based marker in childhood acute lymphoblastic leukemia. Tumour Biol. 2016; 37(8):10571-6. DOI: 10.1007/s13277-016-4948-7. View

12.

Xiong Y, Li Z, Ji M, Tan A, Bemis J, Tse J . MIR29B regulates expression of MLLT11 (AF1Q), an MLL fusion partner, and low MIR29B expression associates with adverse cytogenetics and poor overall survival in AML. Br J Haematol. 2011; 153(6):753-7. PMC: 3896048. DOI: 10.1111/j.1365-2141.2011.08662.x. View

13.

Nicot C, Mahieux R, Opavsky R, Cereseto A, Wolff L, Brady J . HTLV-I Tax transrepresses the human c-Myb promoter independently of its interaction with CBP or p300. Oncogene. 2000; 19(17):2155-64. DOI: 10.1038/sj.onc.1203536. View

14.

Merkel O, Asslaber D, Pinon J, Egle A, Greil R . Interdependent regulation of p53 and miR-34a in chronic lymphocytic leukemia. Cell Cycle. 2010; 9(14):2764-8. View

15.

Zenz T, Eichhorst B, Busch R, Denzel T, Habe S, Winkler D . TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol. 2010; 28(29):4473-9. DOI: 10.1200/JCO.2009.27.8762. View

16.

Guo G, Kang Q, Chen Q, Chen Z, Wang J, Tan L . High expression of long non-coding RNA H19 is required for efficient tumorigenesis induced by Bcr-Abl oncogene. FEBS Lett. 2014; 588(9):1780-6. DOI: 10.1016/j.febslet.2014.03.038. View

17.

Mraz M, Dolezalova D, Plevova K, Stano Kozubik K, Mayerova V, cerna K . MicroRNA-650 expression is influenced by immunoglobulin gene rearrangement and affects the biology of chronic lymphocytic leukemia. Blood. 2012; 119(9):2110-3. DOI: 10.1182/blood-2011-11-394874. View

18.

Taganov K, Boldin M, Chang K, Baltimore D . NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A. 2006; 103(33):12481-6. PMC: 1567904. DOI: 10.1073/pnas.0605298103. View

19.

Ohyashiki J, Umezu T, Kobayashi C, Hamamura R, Tanaka M, Kuroda M . Impact on cell to plasma ratio of miR-92a in patients with acute leukemia: in vivo assessment of cell to plasma ratio of miR-92a. BMC Res Notes. 2010; 3:347. PMC: 3022817. DOI: 10.1186/1756-0500-3-347. View

20.

Agirre X, Jimenez-Velasco A, Jose-Eneriz E, Garate L, Bandres E, Cordeu L . Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth. Mol Cancer Res. 2008; 6(12):1830-40. DOI: 10.1158/1541-7786.MCR-08-0167. View